BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cappellacci L, Perinelli DR, Maggi F, Grifantini M, Petrelli R. Recent Progress in Histone Deacetylase Inhibitors as Anticancer Agents. Curr Med Chem 2020;27:2449-93. [PMID: 30332940 DOI: 10.2174/0929867325666181016163110] [Cited by in Crossref: 26] [Cited by in F6Publishing: 31] [Article Influence: 13.0] [Reference Citation Analysis]
Number Citing Articles
1 Busato F, Khouzai BE, Mognato M. Biological Mechanisms to Reduce Radioresistance and Increase the Efficacy of Radiotherapy: State of the Art. IJMS 2022;23:10211. [DOI: 10.3390/ijms231810211] [Reference Citation Analysis]
2 Zhu H, Tan Y, He C, Liu Y, Duan Y, Zhu W, Zheng T, Li D, Xu J, Yang DH, Chen ZS, Xu S. Discovery of a Novel Vascular Disrupting Agent Inhibiting Tubulin Polymerization and HDACs with Potent Antitumor Effects. J Med Chem 2022. [PMID: 35926141 DOI: 10.1021/acs.jmedchem.2c00681] [Reference Citation Analysis]
3 Alseksek RK, Ramadan WS, Saleh E, El-awady R. The Role of HDACs in the Response of Cancer Cells to Cellular Stress and the Potential for Therapeutic Intervention. IJMS 2022;23:8141. [DOI: 10.3390/ijms23158141] [Reference Citation Analysis]
4 Li J, Yu C, Shen F, Cui B, Liu N, Zhuang S. Class IIa histone deacetylase inhibition ameliorates acute kidney injury by suppressing renal tubular cell apoptosis and enhancing autophagy and proliferation. Front Pharmacol 2022;13:946192. [DOI: 10.3389/fphar.2022.946192] [Reference Citation Analysis]
5 Sedky NK, Hamdan AA, Emad S, Allam AL, Ali M, Tolba MF. Insights into the therapeutic potential of histone deacetylase inhibitor/immunotherapy combination regimens in solid tumors. Clin Transl Oncol 2022;24:1262-73. [PMID: 35066777 DOI: 10.1007/s12094-022-02779-x] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Milan TM, Eskenazi APE, Bighetti-trevisan RL, de Almeida LO. Epigenetic modifications control loss of adhesion and aggressiveness of cancer stem cells derived from head and neck squamous cell carcinoma with intrinsic resistance to cisplatin. Archives of Oral Biology 2022. [DOI: 10.1016/j.archoralbio.2022.105468] [Reference Citation Analysis]
7 Pei H, Guo W, Peng Y, Xiong H, Chen Y. Targeting key proteins involved in transcriptional regulation for cancer therapy: Current strategies and future prospective. Med Res Rev 2022. [PMID: 35312190 DOI: 10.1002/med.21886] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
8 Huo M, Zhang J, Huang W, Wang Y. Interplay Among Metabolism, Epigenetic Modifications, and Gene Expression in Cancer. Front Cell Dev Biol 2021;9:793428. [PMID: 35004688 DOI: 10.3389/fcell.2021.793428] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
9 Feng Y, Lu Y, Li J, Zhang H, Li Z, Feng H, Deng X, Liu D, Shi T, Jiang W, He Y, Zhang J, Wang Z. Design, synthesis and biological evaluation of novel o-aminobenzamide derivatives as potential anti-gastric cancer agents in vitro and in vivo. Eur J Med Chem 2022;227:113888. [PMID: 34628244 DOI: 10.1016/j.ejmech.2021.113888] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
10 Ibrahim HS, Abdelsalam M, Zeyn Y, Zessin M, Mustafa AM, Fischer MA, Zeyen P, Sun P, Bülbül EF, Vecchio A, Erdmann F, Schmidt M, Robaa D, Barinka C, Romier C, Schutkowski M, Krämer OH, Sippl W. Synthesis, Molecular Docking and Biological Characterization of Pyrazine Linked 2-Aminobenzamides as New Class I Selective Histone Deacetylase (HDAC) Inhibitors with Anti-Leukemic Activity. Int J Mol Sci 2021;23:369. [PMID: 35008795 DOI: 10.3390/ijms23010369] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
11 Tang Q, Yu YT, Zhang HL, Wang Y, Liu J, Yang SP, Liu JG. NIR light-controlled mitochondria-targeted delivery of carbon monoxide combined with histone deacetylase inhibition for synergistic anticancer therapy. J Inorg Biochem 2022;226:111656. [PMID: 34798307 DOI: 10.1016/j.jinorgbio.2021.111656] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Bai SY, Li ML, Ren Y, Su XM. HDAC8-inhibitor PCI-34051-induced exosomes inhibit human bronchial smooth muscle cell proliferation via miR-381-3p mediated TGFB3. Pulm Pharmacol Ther 2021;71:102096. [PMID: 34740750 DOI: 10.1016/j.pupt.2021.102096] [Reference Citation Analysis]
13 Ma C, Taghour MS, Belal A, Mehany ABM, Mostafa N, Nabeeh A, Eissa IH, Al-Karmalawy AA. Design and Synthesis of New Quinoxaline Derivatives as Potential Histone Deacetylase Inhibitors Targeting Hepatocellular Carcinoma: In Silico, In Vitro, and SAR Studies. Front Chem 2021;9:725135. [PMID: 34631658 DOI: 10.3389/fchem.2021.725135] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
14 Xiao W, Zhou Q, Wen X, Wang R, Liu R, Wang T, Shi J, Hu Y, Hou J. Small-Molecule Inhibitors Overcome Epigenetic Reprogramming for Cancer Therapy. Front Pharmacol 2021;12:702360. [PMID: 34603017 DOI: 10.3389/fphar.2021.702360] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
15 Patel RP, Thomas JR, Curt KM, Fitzsimmons CM, Batista PJ, Bates SE, Gottesman MM, Robey RW. Dual Inhibition of Histone Deacetylases and the Mechanistic Target of Rapamycin Promotes Apoptosis in Cell Line Models of Uveal Melanoma. Invest Ophthalmol Vis Sci 2021;62:16. [PMID: 34533562 DOI: 10.1167/iovs.62.12.16] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
16 Bieszczad B, Garbicz D, Świtalska M, Dudek MK, Warszycki D, Wietrzyk J, Grzesiuk E, Mieczkowski A. Improved HDAC Inhibition, Stronger Cytotoxic Effect and Higher Selectivity against Leukemias and Lymphomas of Novel, Tricyclic Vorinostat Analogues. Pharmaceuticals (Basel) 2021;14:851. [PMID: 34577551 DOI: 10.3390/ph14090851] [Reference Citation Analysis]
17 Buonvicino D, Ranieri G, Chiarugi A. Treatment with Non-specific HDAC Inhibitors Administered after Disease Onset does not Delay Evolution in a Mouse Model of Progressive Multiple Sclerosis. Neuroscience 2021;465:38-45. [PMID: 33862148 DOI: 10.1016/j.neuroscience.2021.04.002] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
18 Takahashi K, Takenaka M, Okamoto A, Bowtell DDL, Kohno T. Treatment Strategies for ARID1A-Deficient Ovarian Clear Cell Carcinoma. Cancers (Basel) 2021;13:1769. [PMID: 33917230 DOI: 10.3390/cancers13081769] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
19 Di Fede E, Ottaviano E, Grazioli P, Ceccarani C, Galeone A, Parodi C, Colombo EA, Bassanini G, Fazio G, Severgnini M, Milani D, Verduci E, Vaccari T, Massa V, Borghi E, Gervasini C. Insights into the Role of the Microbiota and of Short-Chain Fatty Acids in Rubinstein-Taybi Syndrome. Int J Mol Sci 2021;22:3621. [PMID: 33807238 DOI: 10.3390/ijms22073621] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
20 Blaszczak W, Liu G, Zhu H, Barczak W, Shrestha A, Albayrak G, Zheng S, Kerr D, Samsonova A, La Thangue NB. Immune modulation underpins the anti-cancer activity of HDAC inhibitors. Mol Oncol 2021. [PMID: 33773029 DOI: 10.1002/1878-0261.12953] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
21 Oleksiewicz U, Machnik M. Causes, effects, and clinical implications of perturbed patterns within the cancer epigenome. Semin Cancer Biol 2020:S1044-579X(20)30274-1. [PMID: 33359485 DOI: 10.1016/j.semcancer.2020.12.014] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
22 Luo Y, Li H. Structure-Based Inhibitor Discovery of Class I Histone Deacetylases (HDACs). Int J Mol Sci 2020;21:E8828. [PMID: 33266366 DOI: 10.3390/ijms21228828] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
23 Ahmed AA, Neidle S. A G-Quadruplex-Binding Small Molecule and the HDAC Inhibitor SAHA (Vorinostat) Act Synergistically in Gemcitabine-Sensitive and Resistant Pancreatic Cancer Cells. Molecules 2020;25:E5407. [PMID: 33227941 DOI: 10.3390/molecules25225407] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
24 Kaur M, Loveleen, Kumar R. Inhibition of histone deacetylases, topoisomerases and epidermal growth factor receptor by metal-based anticancer agents: Design & synthetic strategies and their medicinal attributes. Bioorg Chem 2020;105:104396. [PMID: 33130345 DOI: 10.1016/j.bioorg.2020.104396] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
25 Shirbhate E, Patel P, Patel VK, Veerasamy R, Sharma PC, Rajak H. The combination of histone deacetylase inhibitors and radiotherapy: a promising novel approach for cancer treatment. Future Oncol 2020;16:2457-69. [PMID: 32815411 DOI: 10.2217/fon-2020-0385] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
26 Neganova ME, Klochkov SG, Aleksandrova YR, Aliev G. Histone modifications in epigenetic regulation of cancer: Perspectives and achieved progress. Semin Cancer Biol 2020:S1044-579X(20)30176-0. [PMID: 32814115 DOI: 10.1016/j.semcancer.2020.07.015] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 10.0] [Reference Citation Analysis]
27 Milazzo G, Mercatelli D, Di Muzio G, Triboli L, De Rosa P, Perini G, Giorgi FM. Histone Deacetylases (HDACs): Evolution, Specificity, Role in Transcriptional Complexes, and Pharmacological Actionability. Genes (Basel) 2020;11:E556. [PMID: 32429325 DOI: 10.3390/genes11050556] [Cited by in Crossref: 39] [Cited by in F6Publishing: 73] [Article Influence: 19.5] [Reference Citation Analysis]
28 Beyer M, Romanski A, Mustafa AM, Pons M, Büchler I, Vogel A, Pautz A, Sellmer A, Schneider G, Bug G, Krämer OH. HDAC3 Activity is Essential for Human Leukemic Cell Growth and the Expression of β-catenin, MYC, and WT1. Cancers (Basel) 2019;11:E1436. [PMID: 31561534 DOI: 10.3390/cancers11101436] [Cited by in Crossref: 6] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
29 Kim Y, Wang SE, Jiang YH. Epigenetic therapy of Prader-Willi syndrome. Transl Res 2019;208:105-18. [PMID: 30904443 DOI: 10.1016/j.trsl.2019.02.012] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 6.7] [Reference Citation Analysis]
30 Ventero MP, Fuentes-Baile M, Quereda C, Perez-Valeciano E, Alenda C, Garcia-Morales P, Esposito D, Dorado P, Manuel Barbera V, Saceda M. Radiotherapy resistance acquisition in Glioblastoma. Role of SOCS1 and SOCS3. PLoS One 2019;14:e0212581. [PMID: 30811476 DOI: 10.1371/journal.pone.0212581] [Cited by in Crossref: 16] [Cited by in F6Publishing: 24] [Article Influence: 5.3] [Reference Citation Analysis]
31 Yang F, Zhao N, Ge D, Chen Y. Next-generation of selective histone deacetylase inhibitors. RSC Adv 2019;9:19571-83. [DOI: 10.1039/c9ra02985k] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 11.0] [Reference Citation Analysis]